European Journal of Clinical Pharmacology

, Volume 68, Issue 2, pp 221–222

Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina

  • Guillaume Moulis
  • Arnaud Batz
  • Geneviève Durrieu
  • Caroline Viard
  • Stéphane Decramer
  • Jean-Louis Montastruc
Letter to the Editors

References

  1. 1.
    Kulshreshtha A, Zacharia AJ, Jarouliya U, Bhadauriya P, Prasad GBKS, Bisen PS (2008) Spirulina in health care management. Curr Pharm Biotechnol 9:400–405PubMedCrossRefGoogle Scholar
  2. 2.
    Deng R, Chow T-J (2010) Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina. Cardiovasc Ther 28:e33–e45PubMedCrossRefGoogle Scholar
  3. 3.
    Teas J, Hebert JR, Fitton JH, Zimba PV (2004) Algae – a poor man’s HAART? Med Hypotheses 62:507–510PubMedCrossRefGoogle Scholar
  4. 4.
    The use of the WHO-UMC system for standardised case causality assessment. The Uppsala Monitoring Center. http://www.who-umc.org/Graphics/24734.pdf. Accessed 8 July 2011
  5. 5.
    Yang Y, Park Y, Cassada DA, Snow DD, Rogers DG, Lee J (2011) In vitro and in vivo safety assessment of edible blue-green algae. Nostoc commune var. sphaeroides Kützing and Spirulina plantensis. Food Chem Toxicol 49:1560–1564PubMedCrossRefGoogle Scholar
  6. 6.
    Rellán S, Osswald J, Saker M, Gago-Martinez A, Vasconcelos V (2009) First detection of anatoxin-a in human and animal dietary supplements containing cyanobacteria. Food Chem Toxicol 47:2189–2195PubMedCrossRefGoogle Scholar
  7. 7.
    Petrus M, Culerrier R, Campistron M, Barre A, Rougé P (2010) First case report of anaphylaxis to spirulin: identification of phycocyanin as responsible allergen. Allergy 65:924–925PubMedCrossRefGoogle Scholar
  8. 8.
    Konno T, Umeda Y, Umeda M, Kawachi I, Oyake M, Fujita N (2011) A case of inflammatory myopathy with widely skin rash following use of supplements containing Spirulina. Rinsho Shinkeigaku 51:330–333PubMedCrossRefGoogle Scholar
  9. 9.
    Lee AN, Werth VP (2004) Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol 140:723–727PubMedCrossRefGoogle Scholar
  10. 10.
    Carmichael WW (1994) The toxins of cyanobacteria. Sci Am 270:78–86PubMedCrossRefGoogle Scholar
  11. 11.
    Carmichael WW, Azevedo SM, An JS et al (2001) Human fatalities from cyanobacteria: chemical and biological evidence for cyanotoxins. Environ Health Perspect 109:663–668PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Guillaume Moulis
    • 1
  • Arnaud Batz
    • 1
  • Geneviève Durrieu
    • 1
  • Caroline Viard
    • 2
  • Stéphane Decramer
    • 3
  • Jean-Louis Montastruc
    • 1
  1. 1.Service de Pharmacologie Clinique, Faculté de Médecine, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, Unité INSERM U 1027Centre Hospitalier Universitaire de Toulouse, Université de ToulouseToulouseFrance
  2. 2.Pharmacie hospitalière, Département de PédiatrieCentre Hospitalier Universitaire de Toulouse, Université de ToulouseToulouse Cedex 9France
  3. 3.Service de Pédiatrie, Département de Néphrologie, Médecine Interne, HypertensionCentre Hospitalier Universitaire de Toulouse, Université de Toulouse, FranceToulouse Cedex 9France

Personalised recommendations